Drug Trial Radar · NCT06964087
Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Apr 23, 2026
Primary completion
May 31, 2027
Study completion Aug 19, 2028
Sponsor
- Lead sponsor
- Op-T LLCIndustry
- Sponsor type
- Industry
- First posted
- May 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will examine the safety of three times weekly SC injections of OPT101 at each of three dose levels over two weeks as well as one year of treatment with SC OPT101 or placebo to match at a single dose level.
Conditions
- Type I Diabetes
Interventions
OPT101Drug
Subcutaneous injection.
OPT101 Placebo to Match (PTM)Other
5% Dextrose (w/v)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in C-peptide (ng/mL)Time frame: 48-week
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham - Department of Medicina
Birmingham, Alabama · Recruiting
Diablo Clinical Research Center
Walnut Creek, California · Recruiting
Barbara Davis Center - University of Colorado Anschuttz Medical Campus
Aurora, Colorado · Recruiting
University of Chicago Medical Center
Chicago, Illinois · Recruiting
Rainier Clinical Research Center
Renton, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.